Alkermes (ALKS) Profit After Tax Growth (1y) (2011 - 2026)
Alkermes (ALKS) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 67.73% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.33% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1,682.88% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Alkermes | 8.78 Bn | 8.26 Bn | 331.33 Mn | -399.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -399.54% |
| Dec 31, 2025 | -67.03% |
| Sep 30, 2025 | -10.04% |
| Jun 30, 2025 | -4.66% |
| Mar 31, 2025 | -39.00% |
| Dec 31, 2024 | 26.58% |
| Sep 30, 2024 | 88.07% |
| Jun 30, 2024 | -61.46% |
| Mar 31, 2024 | 188.01% |
| Dec 31, 2023 | 509.65% |
| Sep 30, 2023 | 174.06% |
| Jun 30, 2023 | 886.65% |
| Mar 31, 2023 | -16.55% |
| Dec 31, 2022 | -3,336.43% |
| Sep 30, 2022 | -128.79% |
| Jun 30, 2022 | -1,374.79% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | 102.05% |
| Sep 30, 2021 | -3,555.49% |
| Jun 30, 2021 | 108.03% |